Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy

American Journal of Obstetrics and Gynecology

Volumn 181, Issue 5 I, 1999, Pages 1113-1117

  Casele, H L ^a   Laifer, S A ^a   Woelkers, D A ^a   Venkataramanan, R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Low molecular weight heparin; Pharmacokinetics; Pregnancy

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; KIDNEY CLEARANCE; PREGNANCY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THIRD TRIMESTER PREGNANCY;

EID: 0032738711     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70091-8     Document Type: Conference Paper

References (17)

1. LA Barbour JM Smith RA. Marlar Heparin levels to guide thromboembolism prophylaxis during pregnancy Am J Obstet Gynecol 173 1995 1869 1873
2. LR Brancazio KA Roperti R Stierer SA. Laifer Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy Am J Obstet Gynecol 173 1995 1240 1245
3. F Forestier F Daffos M Rainaut F. Toulemonde Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy [letter] Thromb Haemost 57 1987 234
4. A Omri JF Delaloye H Andersen F. Bachmann Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy Thromb Haemost 61 1989 55 56
5. JI. Weitz Low molecular-weight heparins N Engl J Med 337 1997 688 698
6. H Casele S. Laifer Prospective evaluation of bone density changes in women on Lovenox Am J Obstet Gynecol 178 1998 S65
7. U Abildgaard L Norhein AE Larsen A Nesvold PM. Sandset Monitoring therapy with LMW heparin: a comparison of three chromogenic substrate assays and the Heptest clotting assay Haemostasis 20 1990 255 258
8. M Gibaldi D. Perrier Pharmacokinetics 2nd ed 1982 Marcel Dekker New York
9. J Fareed W Jeske Hoppensteadt R Clarizio JM. Walenga Are the available low molecular weight heparin preparations the same? Semin Thromb Hemost 22 Suppl 1 1996 77 91
10. R Losito C. Losito Molecular weight of heparin versus biological activity Semin Thromb Hemost 11 1985 29 33
11. A Iorio G. Agnelli Pharmacokinetic optimization of the treatment of deep vein thrombosis Clin Pharmacokinet 32 1997 145 172
12. F Collignon A Frydman H Caplain ML Ozoux Y Le Roux J Bouthier Comparison of the pharmacokinetic profiles of three low molecular mass heparin—Dalteparin, Enoxaparin and Nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism) Thromb Haemost 73 1995 630 640
13. M Blomback K Bremme M Hellgren H. Lindberg A pharmacokinetic study of dalteparin (Fragmin) in late pregnancy Blood Coagul Fibrinolysis 9 1998 343 350
14. MA Badaracco MP. Vessey Recurrence of venous thromboembolism and the use of oral contraceptives BMJ 1 1974 215 217
15. W Evans SA Laifer McNanley A. Ruzycky Management of thromboembolic disease associated with pregnancy J Matern Fetal Med 6 1997 21 27
16. TE Spiro GJ Johnson MJ Christie RM Lyons DE MacFarlane RB Blasier Efficacy and safety to prevent deep venous thrombosis after hip replacement surgery Ann Intern Med 121 1994 81 89
17. MR Toglia JG. Weg Venous thromboembolism during pregnancy N Engl J Med 335 1996 108 114